|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Purinergic receptor P2Y<sub>12</sub> (P2Y<sub>12</sub> ), a G protein-coupled purinergic receptor, is widely distributed in nervous system and involved in the progression of neurological diseases such as multiple sclerosis and neuropathic pain.
|
29341465 |
2019 |
|
Multiple Sclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In particular, ionotropic purinergic receptors P2X4 and P2X7 and metabotropic receptor P2Y12 are differently expressed along the disease and their activation or blockage modifies the course of texperimental autoimmune encephalomyelitis (EAE), the dominant animal model of MS.
|
30500565 |
2019 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recently, numerous evidences further suggested the significance of P2X7R in the pathogenesis of autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), inflammatory bowel disease (IBD), multiple sclerosis (MS), etc.
|
31181327 |
2019 |
|
Mood Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Additionally, recent studies have linked P2RX7 gene variants with the risk of rapid cycling in clinical cohorts of patients with bipolar disorder, as well as other mood disorders.
|
30445384 |
2019 |
|
Mood Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The Gln460Arg (rs2230912) polymorphism of the P2RX7 gene has been widely studied in mood disorders, however the results are still controversial.
|
30664971 |
2019 |
|
Bipolar Disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Comprehensive investigation of the P2X7R Gln460Arg missense mutation (rs2230912), which has been associated with major depression and bipolar disorder, has substantially contributed to validate P2X7R as a potential genetic risk factor.
|
30093269 |
2018 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
In a model of BCG-induced depression, JNJ-55308942 dosed orally (30 mg/kg), reversed the BCG-induced deficits of sucrose preference and social interaction, indicating for the first time a role of P2X7 in the BCG model of depression, probably due to the neuroinflammatory component induced by BCG inoculation.
|
30026598 |
2018 |
|
Mental Depression
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The P2RX7 polymorphism rs2230912 is associated with depression: A meta-analysis.
|
29122639 |
2018 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
A P2X7 receptor antagonist reverses behavioural alterations, microglial activation and neuroendocrine dysregulation in an unpredictable chronic mild stress (UCMS) model of depression in mice.
|
30015007 |
2018 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
P2X7 Receptor: A Potential Therapeutic Target for Depression?
|
30093269 |
2018 |
|
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
In a model of BCG-induced depression, JNJ-55308942 dosed orally (30 mg/kg), reversed the BCG-induced deficits of sucrose preference and social interaction, indicating for the first time a role of P2X7 in the BCG model of depression, probably due to the neuroinflammatory component induced by BCG inoculation.
|
30026598 |
2018 |
|
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
A P2X7 receptor antagonist reverses behavioural alterations, microglial activation and neuroendocrine dysregulation in an unpredictable chronic mild stress (UCMS) model of depression in mice.
|
30015007 |
2018 |
|
Depressive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The P2RX7 polymorphism rs2230912 is associated with depression: A meta-analysis.
|
29122639 |
2018 |
|
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
We propose that P2X7R is a putative target with good prospects for therapeutic intervention in depressive disorders.
|
30093269 |
2018 |
|
Mood Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
We also highlight recent advances in drug discovery and development of P2X7 small molecule antagonists and P2X7 PET ligands which provide optimism that clinical tools are availableto address critical proof-of-concept experiments in mood disorders.
|
30121550 |
2018 |
|
Mood Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Various studies have investigated whether single nucleotide polymorphisms (SNPs) in the gene purinergic receptor P2X7 (P2RX7), and rs2230912 specifically, were associated with mood disorders.
|
29122639 |
2018 |
|
Mood Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
In this review, we will discuss the recent progress in understanding the role of the P2X7 receptor in the pathogenesis and development of mood disorders and in discovering CNS-penetrable P2X7 antagonists for potential uses in in vivo imaging to monitor brain inflammation and antidepressant therapeutics.
|
29453990 |
2018 |
|
Bipolar Disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These results indicate that heterozygosity for the wild-type P2X7R and its mood disorder-associated variant P2X7R-Gln460Arg represents a genetic risk factor, which is potentially able to convey susceptibility to mood disorders.<b>SIGNIFICANCE STATEMENT</b> Depression and bipolar disorder are the most common mood disorders.
|
29079688 |
2017 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we investigated the role of P2X7R in the pathogenesis of depression.
|
28486969 |
2017 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
The use in particular of P2X7 receptor antagonists for the treatment of neurodegenerative diseases, cancer, depression, stroke and ischaemia, A2A receptor antagonists for Parkinson's disease and agonists for brain injury and depression and P2X3 receptor antagonists for migraine and seizures has been recommended.
|
27658510 |
2017 |
|
Mental Depression
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These results indicate that heterozygosity for the wild-type P2X7R and its mood disorder-associated variant P2X7R-Gln460Arg represents a genetic risk factor, which is potentially able to convey susceptibility to mood disorders.<b>SIGNIFICANCE STATEMENT</b> Depression and bipolar disorder are the most common mood disorders.
|
29079688 |
2017 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings suggest the endogenous activation of P2rx7s in the learned helplessness model of depression and decreased plasticity of spine synapses in P2rx7-deficient mice might explain the resistance of these animals to repeated stressful stimuli.
|
28633291 |
2017 |
|
Depressive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These results indicate that heterozygosity for the wild-type P2X7R and its mood disorder-associated variant P2X7R-Gln460Arg represents a genetic risk factor, which is potentially able to convey susceptibility to mood disorders.<b>SIGNIFICANCE STATEMENT</b> Depression and bipolar disorder are the most common mood disorders.
|
29079688 |
2017 |
|
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings suggest the endogenous activation of P2rx7s in the learned helplessness model of depression and decreased plasticity of spine synapses in P2rx7-deficient mice might explain the resistance of these animals to repeated stressful stimuli.
|
28633291 |
2017 |
|
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
The use in particular of P2X7 receptor antagonists for the treatment of neurodegenerative diseases, cancer, depression, stroke and ischaemia, A2A receptor antagonists for Parkinson's disease and agonists for brain injury and depression and P2X3 receptor antagonists for migraine and seizures has been recommended.
|
27658510 |
2017 |